These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
218 related articles for article (PubMed ID: 10326114)
1. Clinical safety of a polyvalent F(ab')2 equine antivenom in 223 African snake envenomations: a field trial in Cameroon. VAO (Venin Afrique de l'Ouest) Investigators. Chippaux JP; Lang J; Eddine SA; Fagot P; Rage V; Peyrieux JC; Le Mener V Trans R Soc Trop Med Hyg; 1998; 92(6):657-62. PubMed ID: 10326114 [TBL] [Abstract][Full Text] [Related]
2. Short report: treatment of snake envenomations by a new polyvalent antivenom composed of highly purified F(ab)2: results of a clinical trial in northern Cameroon. Chippaux JP; Lang J; Amadi-Eddine S; Fagot P; Le Mener V Am J Trop Med Hyg; 1999 Dec; 61(6):1017-8. PubMed ID: 10674688 [TBL] [Abstract][Full Text] [Related]
3. First clinical experiences with a new ovine Fab Echis ocellatus snake bite antivenom in Nigeria: randomized comparative trial with Institute Pasteur Serum (Ipser) Africa antivenom. Meyer WP; Habib AG; Onayade AA; Yakubu A; Smith DC; Nasidi A; Daudu IJ; Warrell DA; Theakston RD Am J Trop Med Hyg; 1997 Mar; 56(3):291-300. PubMed ID: 9129531 [TBL] [Abstract][Full Text] [Related]
4. [Snake bite by European vipers. A multicenter study of tolerance to Viperfav, a new intravenous antivenom]. de Haro L; Lang J; Bedry R; Guelon D; Harry P; Marchal-Mazet F; Jouglard J Ann Fr Anesth Reanim; 1998; 17(7):681-7. PubMed ID: 9750806 [TBL] [Abstract][Full Text] [Related]
5. Comparison of F(ab')2 versus Fab antivenom for pit viper envenomation: a prospective, blinded, multicenter, randomized clinical trial. Bush SP; Ruha AM; Seifert SA; Morgan DL; Lewis BJ; Arnold TC; Clark RF; Meggs WJ; Toschlog EA; Borron SW; Figge GR; Sollee DR; Shirazi FM; Wolk R; de Chazal I; Quan D; García-Ubbelohde W; Alagón A; Gerkin RD; Boyer LV Clin Toxicol (Phila); 2015 Jan; 53(1):37-45. PubMed ID: 25361165 [TBL] [Abstract][Full Text] [Related]
6. [Clinical study of tolerance and effectiveness of a F(ab')(2) polyvalent antienom for African snake bites in Kindia, Guinea]. Baldé MC; Chippaux JP; Boiro MY; Stock R; Massougbodji A Bull Soc Pathol Exot; 2012 Aug; 105(3):157-61. PubMed ID: 22359185 [TBL] [Abstract][Full Text] [Related]
7. Clinical trial of an F(ab')2 polyvalent equine antivenom for African snake bites in Benin. Chippaux JP; Massougbodji A; Stock RP; Alagon A; Am J Trop Med Hyg; 2007 Sep; 77(3):538-46. PubMed ID: 17827375 [TBL] [Abstract][Full Text] [Related]
8. Safety of intravenous equine F(ab')2: insights following clinical trials involving 1534 recipients of scorpion antivenom. Boyer L; Degan J; Ruha AM; Mallie J; Mangin E; Alagón A Toxicon; 2013 Dec; 76():386-93. PubMed ID: 23916602 [TBL] [Abstract][Full Text] [Related]
9. First clinical experiences with specific sheep Fab fragments in snake bite. Report of a multicentre study of Vipera berus envenoming. Karlson-Stiber C; Persson H; Heath A; Smith D; al-Abdulla IH; Sjöström L J Intern Med; 1997 Jan; 241(1):53-8. PubMed ID: 9042094 [TBL] [Abstract][Full Text] [Related]
10. Subacute coagulopathy in a randomized, comparative trial of Fab and F(ab')2 antivenoms. Boyer LV; Chase PB; Degan JA; Figge G; Buelna-Romero A; Luchetti C; Alagón A Toxicon; 2013 Nov; 74():101-8. PubMed ID: 23948058 [TBL] [Abstract][Full Text] [Related]
11. Snake bites by European vipers in Mainland France in 2017-2018: comparison of two antivenoms Viperfav Boels D; Hamel JF; Le Roux G; Labadie M; Paret N; Delcourt N; Langrand J; Puskarczyk E; Nisse P; Sinno-Tellier S; de Haro L Clin Toxicol (Phila); 2020 Nov; 58(11):1050-1057. PubMed ID: 32134691 [No Abstract] [Full Text] [Related]
12. Recurrent and persistent coagulopathy following pit viper envenomation. Boyer LV; Seifert SA; Clark RF; McNally JT; Williams SR; Nordt SP; Walter FG; Dart RC Arch Intern Med; 1999 Apr; 159(7):706-10. PubMed ID: 10218750 [TBL] [Abstract][Full Text] [Related]
13. Coagulation parameters in copperhead compared to other Crotalinae envenomation: secondary analysis of the F(ab') Gerardo CJ; Vissoci JR; Brown MW; Bush SP Clin Toxicol (Phila); 2017 Feb; 55(2):109-114. PubMed ID: 27806644 [TBL] [Abstract][Full Text] [Related]
14. Antivenom treatment in Vipera berus envenoming--report of 30 cases. Karlson-Stiber C; Persson H J Intern Med; 1994 Jan; 235(1):57-61. PubMed ID: 8283161 [TBL] [Abstract][Full Text] [Related]
15. Low incidence of early reactions to horse-derived F(ab')(2) antivenom for snakebites in Thailand. Thiansookon A; Rojnuckarin P Acta Trop; 2008 Feb; 105(2):203-5. PubMed ID: 17996842 [TBL] [Abstract][Full Text] [Related]
16. European viper envenomings: Assessment of Viperfav™ and other symptomatic treatments. Boels D; Hamel JF; Bretaudeau Deguigne M; Harry P Clin Toxicol (Phila); 2012 Mar; 50(3):189-96. PubMed ID: 22372786 [TBL] [Abstract][Full Text] [Related]
17. A prospective multicenter observational study of Viperidae polyvalent immune F(ab') Vanni M; Intorre L; Corazza M; Meucci V; Parti S J Vet Emerg Crit Care (San Antonio); 2020 Jan; 30(1):34-40. PubMed ID: 31858721 [TBL] [Abstract][Full Text] [Related]
18. 272 cases of rattlesnake envenomation in dogs: Demographics and treatment including safety of F(ab')2 antivenom use in 236 patients. Witsil AJ; Wells RJ; Woods C; Rao S Toxicon; 2015 Oct; 105():19-26. PubMed ID: 26341419 [TBL] [Abstract][Full Text] [Related]